Anna Olsson-Brown

Anna Olsson-Brown

Auto-generated profile, based on publicly available information

Anna Olsson-Brown

Department Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology University of Liverpool Liverpool UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2021 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
WYWeiyu Ye
Weiyu Ye
AOAnna Olsson-Brown
Anna Olsson-Brown
RWRobert A. Watson
Robert A. Watson
VCVincent T. F. Cheung
Vincent T. F. Cheung
RMRobert D. Morgan
Robert D. Morgan
BFBenjamin P. Fairfax
Benjamin P. Fairfax
Background: Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear. Methods: Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed. Results: 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment. Conclusions: Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.

26 December 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
AOAnna Olsson-Brown
Anna Olsson-Brown
VYVincent Yip
Vincent Yip
EOEmeka D. Ogiji
Emeka D. Ogiji
CJCarol Jolly
Carol Jolly
LRLorenzo Ressel
Lorenzo Ressel
DCDaniel Carr
Daniel Carr
Stevens‒Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are severe cutaneous adverse drug reactions characterized by widespread keratinocyte cell death and epidermal detachment. At present, there is little understanding of how the detachment occurs or how it is abrogated by the TNF-α inhibitor etanercept, an effective SJS/TEN treatment. RNA sequencing was used to identify upregulated transcripts in formalin-fixed paraffin-embedded SJS/TEN skin biopsies. Epidermal matrix metalloproteinase 9 (MMP9) expression was assessed by immunohistochemistry in skin biopsies and cultured human skin explants exposed to serum from patients with cutaneous adverse drug reactions. TNF-α‒induced MMP9 expression and activity and its abrogation by etanercept were determined using the HaCaT immortalized keratinocyte cell line. Epidermal MMP9 expression was significantly higher in SJS/TEN skin (70.6%) than in healthy control skin (0%) (P = 0.0098) and nonbullous skin reactions (10.7%) (P = 0.0002). SJS/TEN serum induced significant MMP9 expression and collagenase activity in healthy skin explants, which was reduced by etanercept. Etanercept was also able to negate the TNF-α‒induced MMP9 expression in the HaCaT cell line. Data suggest that elevated epidermal MMP9 expression and collagenase activity are a putative pathogenic mechanism in SJS/TEN, which is limited by etanercept. Modulation of MMP9 expression and activity represents, to our knowledge, a previously unreported therapeutic target for the treatment of SJS/TEN.

2 June 2023 in The Journal of Dermatology
Verified
Journal Article
Open access
GNGospel Nwikue
Gospel Nwikue
AOAnna Olsson‐Brown
Anna Olsson‐Brown
NANourah Aboheimed
Nourah Aboheimed
VYVincent Yip
Vincent Yip
CJCarol Jolly
Carol Jolly
DCDaniel Carr
Daniel Carr
Decreased epidermal high‐mobility group box 1 (HMGB1) expression is an early marker of epidermal injury in Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Etanercept, an anti‐tumor necrosis factor therapeutic, is effective in the treatment of SJS/TEN. The objective was to characterize antitumor necrosis factor‐alpha (TNF‐α)‐mediated HMGB1 keratinocyte/epidermal release and etanercept modulation. HMGB1 release from TNF‐α treated (± etanercept), or doxycycline‐inducible RIPK3 or Bak‐expressing human keratinocyte cells (HaCaTs) was determined by western blot/ELISA. Healthy skin explants were treated with TNF‐α or serum (1:10 dilution) from immune checkpoint inhibitor‐tolerant, lichenoid dermatitis or SJS/TEN patients ± etanercept. Histological and immunohistochemical analysis of HMGB1 was undertaken. TNF‐α induced HMGB1 release in vitro via both necroptosis and apoptosis. Exposure of skin explants to TNF‐α or SJS/TEN serum resulted in significant epidermal toxicity/detachment with substantial HMGB1 release which was attenuated by etanercept. Whole‐slide image analysis of biopsies demonstrated significantly lower epidermal HMGB1 in pre‐blistered SJS/TEN versus control (P < 0.05). Keratinocyte HMGB1 release, predominantly caused by necroptosis, can be attenuated by etanercept. Although TNF‐α is a key mediator of epidermal HMGB1 release, other cytokines/cytotoxic proteins also contribute. Skin explant models represent a potential model of SJS/TEN that could be utilized for further mechanistic studies and targeted therapy screening.

20 May 2021 in Journal of Clinical Oncology
Verified
Journal Article
Open access
HAHamzah Abu-Sbeih
Hamzah Abu-Sbeih
TTTenglong Tang
Tenglong Tang
DFDavid M. Faleck
David M. Faleck
MDMichael L. Dougan
Michael L. Dougan
AOAnna Olsson-Brown
Anna Olsson-Brown
Yinghong WangYinghong Wang
Yinghong Wang
2643 Background: Immune checkpoint inhibitor (ICI)-mediated colitis (IMC) is a common and serious adverse event. Although small series have described the clinical presentation of IMC, large multicenter series that integrate clinical, endoscopic, and histologic findings are lacking. Methods: We retrospectively assessed patients who received ICI and had endoscopically confirmed IMC from 2010 to 2019. IMC was graded based on the CTCAE version 5.0 criteria. Multivariate logistic regression analyses were conducted to assess factors associated with recurrence of IMC symptoms and long duration of corticosteroids use (> 70 days). Results: 675 patients were included. 387 patients were males (57%). Median age was 63 years. Melanoma was the most common cancer type (327; 48%). Most (365; 54%) patients received CTLA-4 inhibitor ICI, as monotherapy or in combination with PD-(L)1. Median time from ICI therapy to IMC was 62 days. IMC was grade 2 in 335 (50%) patients, Grade 3 in 181 (27%), and grade 4 in 16 (3%). 155 (23%) patients had mucosal ulceration on endoscopy, 91 of them had severe features (deep, large, or multiple ulcers); 336 (50%) patients had non-ulcerative inflammation. The rest had normal endoscopic findings with histologic inflammation. Most patients were admitted to the hospital for management of IMC (405; 60%) and 16 (3%) needed ICU-level of care. Treatment included corticosteroids in 577 (85%) patients (median duration 52 days), TNF inhibitor in 245 (36%), and vedolizumab in 90 (13%). 202 (32%) patients had recurrent IMC after resolution of symptoms. On multivariate logistic regression, factors associated with IMC recurrence and long (> 70 days) duration of corticosteroid therapy were grade of IMC ( p = 0.049), treatment with infliximab or vedolizumab ( p = 0.044), presence of mucosal ulceration ( p = 0.034 ), or features of active histologic inflammation ( p = 0.076). Of note, patients with mucosal ulceration received infliximab or vedolizumab more frequently ( p < 0.001). For patients with grade 2 IMC, mucosal inflammation on endoscopy and delay in performing endoscopy with time from IMC onset to endoscopy more than a month were associated with IMC recurrence and longer duration of corticosteroid use ( p = 0.029 and p < 0.001, respectively). 16 (3%) patients had colonic perforation, 7 of them underwent surgical resection. No IMC-related death occurred. Conclusions: IMC is a clinically significant adverse event that can lead to premature termination of ICI therapy with high rates of hospital admission. Rarely, it results in colonic perforation requiring surgical intervention and ICU admission. Our data suggest that there is a utility of endoscopic and histologic evaluation in the prediction of worse outcomes from IMC. This finding is particularly important for grade 2 IMC as current guidelines do not recommend endoscopic evaluation for this group.

25 January 2019 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
VCV Cheung
V Cheung
Tejpal GuptaTejpal Gupta
Tejpal Gupta
AOA Olsson-Brown
A Olsson-Brown
SSSreedhar Subramanian
Sreedhar Subramanian
MPM Payne
M Payne
OBO Brain
O Brain
Checkpoint inhibitors are a novel anti-cancer therapy that are standard of care in metastatic melanoma, non-small cell lung and renal cancer. CTLA-4 inhibitors (eg, Ipilimumab) and PD-1 inhibitors (Nivolumab, Pembrolizumab) can be used separately or in combination for melanoma, whereas single PD-1 inhibitors are the norm for others. Their immune inhibition is non-specific, leading to a number of immune-related adverse events (irAEs), including colitis, hepatitis, and pancreatitis. Combination therapy is known to cause more irAEs than single-agent PD-1 inhibition. There are limited real-world clinical data describing the incidence and management of these GI irAEs. Retrospective two–centre (John Radcliffe Hospital in Oxford and Clatterbridge Cancer Centre in Liverpool) review. Melanoma, renal and lung cancer patients receiving Ipilimumab ± Nivolumab ± Pembrolizumab between December 2011 and June 2018 were identified from the oncology prescribing database. The electronic patient record (EPR) was used to determine the incidence of GI side effects. Investigations, treatment, and outcome data were collated. Of 1125 patients who had immunotherapy, 130 developed colitis (11.6%). In our cohort: (1) Median age was 66 (Males- Median 67, range 24–88; females: 64.5 range 27–86); (2) 60% were male; (3) 63.0% patients required admission (75% combination); (4) median length of admission is 4–7 days (6 combination); (5) presence of erosions or ulcers at endoscopy tended to predict a more severe outcome; (6) faecal calprotectin in steroid refractory cases was >300 in all patients where measured; (7) high proportion of patients receiving IV methylprednisolone 43.8% (66.7% combination); (8) significant proportion of patients requiring infliximab 21.5% (35% in combination therapy); (9) of those requiring infliximab, 64.3% (18/28) were male; (10) two patients with refractoriness to steroids and infliximab had vedolizumab; (11) colectomy rate 2.3% (3/130). Complete management and outcome data will be presented. Immunotherapy-related colitis is one of the more severe adverse events related to immunotherapy and a significant proportion of patients will require hospital admission. Steroid refractoriness is a significant problem and studies are required to elucidate optimum treatment regimens and escalation strategies. This has implications for standardisation of care and healthcare provision on already stretched budgets. Complete management and outcome data will be presented.

5 June 2020 in Clinical Oncology
Verified
Journal Article
Open access
PDF file
JBJ. Best
J. Best
TST. Starkey
T. Starkey
ACA. Chatterjee
A. Chatterjee
DFD. Fackrell
D. Fackrell
LPL. Pettit
L. Pettit
LLL.Y.W. Lee
L.Y.W. Lee
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: T. Starkey, A. Olsson-Brown, V. Cheng, D.J. Hughes, A.J.X. Lee, K. Purshouse, R. Arnold, C. Palles, S. Sivakumar, J.-B. Cazier and L.Y.W. Lee comprise part of the UK Coronavirus Monitoring Project team, donating time and resources to support the project. No other conflicts of interest are declared.